BPC-157 Oral Administration: The Stability Data
The Real BPC-157 Story
24+ hours
BPC-157 remains structurally intact in human gastric juice for over 24 hours, a property almost unheard of among therapeutic peptides.
Sikiric et al., Current Pharmaceutical Design, 2011
Sikiric et al., Current Pharmaceutical Design, 2011
View as imageMost peptide drugs are destroyed within minutes of reaching the stomach. Pepsin and hydrochloric acid at pH 2.0 cleave peptide bonds efficiently, which is why nearly every peptide therapeutic on the market requires injection. BPC-157 is a notable exception. This 15-amino acid fragment, originally isolated from human gastric juice, remains structurally intact in gastric fluid for over 24 hours.[1] That stability has made it the focus of oral administration research across dozens of animal studies, and it is the reason BPC-157 is one of the only peptides sold in capsule form on the gray market. For the full evidence picture on this compound, see the pillar overview of BPC-157 research.
The gastric stability claim is real, but it does not answer the question most people actually want answered: does oral BPC-157 work for conditions beyond the gastrointestinal tract? That question has a more complicated answer than the stability data alone suggests.
Key Takeaways
- BPC-157 remains intact in human gastric juice for over 24 hours at pH 2.0, resisting both pepsin and trypsin degradation (Sikiric et al., 2011)
- The peptide requires no carrier molecules for oral administration, unlike virtually all other peptide therapeutics (Sikiric et al., 2020)
- Oral BPC-157 at microgram and nanogram doses has shown efficacy in rat models of gastric ulcers, esophageal damage, short bowel syndrome, and NSAID-induced gut injury
- No human pharmacokinetic study has measured oral bioavailability, plasma levels, or systemic absorption after oral dosing
- The only human data (a pilot study in interstitial cystitis) used oral capsules, but did not include pharmacokinetic measurements (Lee et al., 2024)
- Animal studies routinely compare oral and intraperitoneal routes, with both showing activity, but at different effective dose ranges
Where the stability claim comes from
BPC-157's full name is "Body Protection Compound-157," and it was first described in 1993 by Predrag Sikiric's group at the University of Zagreb as a peptide isolated from human gastric juice.[2] The name "stable gastric pentadecapeptide" appears in virtually every publication from this group, and it is not marketing language. The stability has been documented across multiple experiments.
The key evidence comes from incubation studies where BPC-157 was exposed to human gastric juice under physiological conditions (pH 2.0, 37 degrees Celsius, with pepsin present). After 24 hours, the peptide retained its structure as measured by HPLC analysis.[1] This is extraordinary for a linear peptide. Most linear peptides of similar size are degraded within 15-30 minutes under the same conditions. Cyclic peptides and those with D-amino acid substitutions can achieve similar stability, but BPC-157 accomplishes this with standard L-amino acids in a linear chain.
The mechanism behind this stability is not fully characterized. The peptide lacks the specific cleavage sites most vulnerable to pepsin (which preferentially cuts at hydrophobic residues like phenylalanine and leucine). Its amino acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) contains an unusual density of proline residues (three consecutive prolines), which create rigid kinks in the peptide backbone that may resist enzymatic access.
A 2020 comprehensive review from the Zagreb group confirmed that BPC-157 requires no carrier molecules for oral activity, distinguishing it from other peptide therapeutics that depend on protease inhibitors, permeation enhancers, or encapsulation technologies to survive the GI tract.[3]
Oral efficacy in animal models: the gastrointestinal evidence
The strongest evidence for oral BPC-157 comes from gastrointestinal models, which makes intuitive sense: a peptide that survives the stomach would have direct contact with damaged GI tissue after oral dosing.
Gastric ulcers. The earliest and most replicated finding is protection against gastric ulcers. Sikiric et al. (1997) showed that oral BPC-157 reduced NSAID-induced gastric lesions in rats at doses as low as 10 micrograms per kilogram.[4] The peptide also accelerated healing of existing ulcers when given after injury induction. This finding has been replicated across multiple NSAID models (indomethacin, diclofenac) and other ulcer-inducing agents (cysteamine, alcohol). For more on this evidence, see the BPC-157 and gastric ulcers article.
NSAID-induced intestinal damage. Park et al. (2020) demonstrated that BPC-157 rescued NSAID-induced cytotoxicity by stabilizing intestinal permeability and enhancing cytoprotection in both cell culture and rat models.[5] The peptide reduced intestinal permeability markers and preserved tight junction protein expression, suggesting a mechanism beyond simple acid neutralization.
Esophageal injury. Petrovic et al. (2011) reported that oral BPC-157 reduced esophagitis severity in a rat reflux model, with concurrent improvements in lower esophageal sphincter function.[6] Cesarec et al. (2013) extended this to esophagocutaneous fistula healing, where both oral and intraperitoneal routes showed activity.[7]
Short bowel syndrome. Sever et al. (2009) tested oral BPC-157 in rats after massive intestinal resection and found improved adaptation of the remaining bowel, including increased villus height and crypt depth, markers of intestinal regenerative capacity.[8]
NSAID toxicity model. Ilic et al. (2011) showed that oral BPC-157 counteracted diclofenac-induced gastrointestinal damage and associated liver and brain lesions in rats, suggesting systemic effects even from oral dosing.[9]
The question of systemic absorption
Gastric stability and gastrointestinal efficacy do not necessarily mean the peptide reaches the bloodstream in meaningful concentrations after oral dosing. This is the critical gap in the BPC-157 evidence base.
No published study has measured plasma BPC-157 concentrations after oral administration in any species. No pharmacokinetic profile (Cmax, Tmax, AUC, half-life) has been reported for the oral route. This is a remarkable omission given that the peptide has been studied for over 30 years.
What exists instead is indirect evidence. Multiple animal studies have compared oral and intraperitoneal (IP) administration routes and found that both produce measurable effects on tissues distant from the GI tract. The Zagreb group has reported oral efficacy in models of tendon healing, burn wounds, corneal injury, and central nervous system disturbances.[10] In many of these studies, the oral doses required for comparable effects were higher than the IP doses, which is consistent with (but does not prove) partial systemic absorption.
A 2025 systematic review of BPC-157 in orthopedic sports medicine confirmed that oral and IP routes are the two most commonly used administration routes across the literature, with some studies using both in the same experimental design.[11] The review noted that dose equivalence between routes has never been formally established.
The Sikiric group has proposed that BPC-157 may exert systemic effects through interactions with the gut-brain axis and the nitric oxide (NO) system rather than requiring high plasma levels. This hypothesis is covered in the BPC-157 and the gut-brain axis article. If correct, it would mean oral BPC-157 could produce distant effects through signaling cascades initiated in the gut, even without significant systemic absorption. This is biologically plausible (the gut communicates with the brain and other organs through vagal, hormonal, and immune pathways) but unproven for BPC-157 specifically.
Why most peptides cannot be taken orally
To appreciate what makes BPC-157 unusual, it helps to understand why oral peptide delivery is one of pharmaceutical science's hardest problems. The article on the future of oral peptide drugs covers the broader landscape in detail.
Enzymatic degradation. The stomach contains pepsin (active at pH 1.5-3.5), and the small intestine adds trypsin, chymotrypsin, and carboxypeptidases. Most peptides are cleaved into inactive fragments before reaching the intestinal epithelium.
Poor membrane permeability. Even if a peptide survives digestion, it must cross the intestinal epithelium to reach the bloodstream. Peptides are generally hydrophilic, charged molecules that cannot passively diffuse through lipid bilayer membranes. They rely on active transport mechanisms that are typically specific to natural dietary amino acids and dipeptides, not 15-amino acid chains.
First-pass metabolism. Peptides absorbed through the intestine enter the portal circulation and pass through the liver before reaching systemic circulation. Hepatic peptidases further degrade any surviving peptide.
The pharmaceutical industry has spent billions addressing these barriers. Oral semaglutide (Rybelsus) uses a carrier molecule called SNAC to enhance absorption across the gastric epithelium, and it achieves only about 1% oral bioavailability. That 1% is considered a breakthrough. BPC-157's claimed carrier-free oral activity, if confirmed in human pharmacokinetic studies, would represent a fundamentally different solution to the oral peptide problem.
The human evidence gap
The most significant limitation of the oral BPC-157 story is the near-total absence of human data. Only one published human study has used oral BPC-157: Lee et al. (2024) conducted a pilot study of oral BPC-157 capsules in patients with interstitial cystitis.[12] The study reported symptom improvement, but it was small, uncontrolled, and did not include pharmacokinetic measurements. It cannot answer the question of how much BPC-157 reached the bloodstream, bladder tissue, or any other target.
The IBD clinical trial that reached Phase II (documented in the ghost trial article) used an unspecified route and never published full results. If oral administration was used, that trial could have provided the first controlled human data on oral BPC-157 efficacy, but the data remains unpublished.
The regulatory situation further complicates research. The FDA's Category 2 classification of BPC-157 has restricted compounding pharmacy access in the United States, making it harder to conduct the kind of clinical studies that would resolve the oral bioavailability question.
What the angiogenesis and NO system data tells us
A 2018 review by Seiwerth et al. examined BPC-157's relationship with standard angiogenic growth factors and its role in gastrointestinal tract healing.[13] The review documented that BPC-157 interacts with the NO system, VEGF, and other growth factor pathways. Importantly, several of these interactions were demonstrated with oral dosing in animal models, suggesting that the peptide's mechanism of action in the GI tract involves signaling through established molecular pathways rather than nonspecific physical protection.
A 2025 review published in Inflammopharmacology provided a comprehensive assessment of BPC-157's cytoprotective properties, confirming that the compound protects the GI tract through multiple mechanisms including maintaining mucosal blood flow, modulating inflammation, and supporting epithelial cell survival.[14] The review emphasized that these effects have been demonstrated with oral administration across numerous animal models, but also noted the absence of controlled human trials.
Oral vs injectable: what the animal data actually shows
In the animal literature, the most commonly used routes are oral (in drinking water or by gavage) and intraperitoneal injection. A smaller number of studies use subcutaneous, intramuscular, or topical routes. The pattern that emerges is:
For GI conditions: Oral administration is the preferred route in the literature and appears to produce robust local effects. Doses typically range from 10 nanograms to 10 micrograms per kilogram. This is consistent with direct contact between the peptide and damaged tissue.
For systemic conditions (tendon, bone, brain, vascular): Both oral and IP routes show activity in animal models, but IP administration tends to produce effects at lower doses. The effective oral dose range for systemic effects is generally higher (microgram to milligram per kilogram range), though precise dose-equivalence data is lacking.
Consistency across routes: The Zagreb group has repeatedly noted that BPC-157 shows "equipotent" activity by oral and parenteral routes in many models.[3] However, "equipotent" in this context typically means both routes produce a statistically significant effect compared to controls, not that identical doses produce identical magnitudes of effect.
The BPC-157 for IBD article and the leaky gut article cover additional oral administration data specific to intestinal conditions.
What remains unknown
The stability of BPC-157 in gastric juice is well-documented. Its oral efficacy in animal GI models is supported by decades of replicated data from the Zagreb group (though independent replication by other labs is limited). What is missing is every piece of pharmacokinetic data that would bridge the gap between animal efficacy and human therapeutic use:
No human oral bioavailability measurements exist. No dose-finding studies in humans have been conducted. No comparisons of oral versus injectable pharmacokinetics have been published in any species. No data exists on whether oral BPC-157 reaches therapeutic concentrations in tissues beyond the GI tract in humans.
These are not trivial gaps. They represent the fundamental information needed to determine whether oral BPC-157 capsules (which are widely sold and consumed) produce any systemic therapeutic effect, or whether their benefits are limited to the GI tract through local contact.
The Bottom Line
BPC-157's gastric stability is genuine and well-documented: the peptide survives over 24 hours in human gastric juice without carriers, a property that is exceptional among linear peptides. Oral administration produces clear efficacy in animal models of GI damage, including ulcers, NSAID injury, esophageal damage, and short bowel syndrome. Evidence for systemic effects from oral dosing exists in animal studies but lacks pharmacokinetic confirmation. No human study has measured oral bioavailability, plasma levels, or dose-response relationships. The stability data supports oral use for GI-targeted applications based on animal evidence, but the extrapolation to systemic benefits in humans remains unvalidated.